Novo Nordisk says experimental drug doxorubicin showed 13% weight loss in trial

Business and Financehealthy

Reuters is first report Early trial data for Novo Nordisk’s much-anticipated experimental drug doxorubicin showed participants lost 13.1% of their weight after 12 weeks, sending the company’s shares to an all-time high and giving it a market value greater than Tesla’s.

market impact

Its shares soared more than 8% to a record high, lifting Novo Nordisk to No. 12 in the ranking of the world’s most valuable companies, from No. 14 previously.

Article tags

Topics of interest: Business and Financehealthy

type: Reuters Best

department: Business and FinancePharmaceuticals and Healthcare

area: America

nation: USA

Winning type: speed

Story type: exclusive/exclusive report

media type: text

Customer Impact: important national stories

Source link

See also  Iceland volcano erupts, lava threatens Grindavik

By Ali Raza

I am a dedicated and skilled News Content Writer with a passion for delivering accurate and engaging stories to a diverse audience. With a solid background in journalism and a keen eye for detail, I bring a commitment to excellence and a deep understanding of the evolving media landscape.

Leave a Reply

Your email address will not be published. Required fields are marked *